Paul  Hudson net worth and biography

Paul Hudson Biography and Net Worth

CEO & Director of Sanofi
Paul Hudson joined Sanofi as CEO on September 1, 2019. 

Previously CEO of Novartis Pharmaceuticals (2016-2019), where he was a member of the Executive Committee, Paul has an expansive international career in healthcare that spans the U.S., Japan and Europe.

Prior to Novartis, he worked for AstraZeneca, where he held several increasingly senior positions and most recently carried out the roles of president, AstraZeneca United States and executive vice president, North America.

He began his career in sales and marketing roles at GlaxoSmithKline UK and Sanofi-Synthélabo U.K. 

Paul holds a degree in economics from Manchester Metropolitan University in the U.K. and last year his alma mater awarded him an honorary Doctor of Business Administration for his achievements in industry. He also holds a diploma in marketing from the Chartered Institute of Marketing, also in the U.K.

How old is Paul Hudson?

Mr. Hudson is currently 57 years old. There are 4 older executives and no younger executives at Sanofi. The oldest executive at Sanofi is Mr. Pierre Chancel, Senior Vice President of Global Diabetes and Senior Vice President of Global Marketing, who is 67 years old. Learn More on Paul Hudson's age.

How do I contact Paul Hudson?

The corporate mailing address for Mr. Hudson and other Sanofi executives is 54 RUE LA BOETIE, PARIS I0, 75008. Sanofi can also be reached via phone at (315) 377-4000 and via email at [email protected]. Learn More on Paul Hudson's contact information.

Has Paul Hudson been buying or selling shares of Sanofi?

Paul Hudson has not been actively trading shares of Sanofi in the last ninety days. Learn More on Paul Hudson's trading history.

Who are Sanofi's active insiders?

Sanofi's insider roster includes Jean-Baptiste de Chatillion (Exec. VP & CFO ), and Paul Hudson (CEO & Director ). Learn More on Sanofi's active insiders.

Paul Hudson Insider Trading History at Sanofi

See Full Table

Paul Hudson Buying and Selling Activity at Sanofi

This chart shows Mr. Paul Hudson's buying and selling at Sanofi by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Sanofi Company Overview

Sanofi logo
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.
Read More

Today's Range

Now: $48.60
Low: $48.30
High: $49.44

50 Day Range

MA: $48.12
Low: $45.75
High: $51.03

2 Week Range

Now: $48.60
Low: $42.63
High: $57.82

Volume

2,414,975 shs

Average Volume

1,855,595 shs

Market Capitalization

$122.94 billion

P/E Ratio

20.59

Dividend Yield

2.86%

Beta

0.61